This functional assay reinforces our proposal that excessive expression of PIR may be a crucial event in tumorigenesis by conferring tumor cells resistance to immune clearance, suggesting that PIR is an emerging target for cancer immune therapy. The gene discussed is PIR; the disease is cancer.